Symbols

SCYX

Scynexis·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SCYX

Scynexis, Inc.

A biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections

Industry

Pharmaceutical

Established Date

11/04/1999

Listing Date

05/02/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.scynexis.com

Security Type

Common stock

Office address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302-6548

Business

Introduction

Scynexis, Inc., was originally incorporated in Delaware on November 4, 1999. Scynexis, Inc., is pioneering innovative medicines that have the potential to help millions of patients around the world who need new options to overcome and prevent difficult-to-treat and drug-resistant infections. Scynexis is developing the lead product candidate ibrexafungerp as a broad-spectrum intravenous (IV)/oral agent for a variety of fungal indications in community and hospital settings. In June 2021 and December 2022, Scynexis announced FDA approval of BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infection, and to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC), respectively. In October 2022, Scynexis announced that it is actively seeking a US commercialization partner to license out BREXAFEMME in order to refocus resources on the clinical development of ibrexafungerp for serious hospital indications, while keeping BREXAFEMME on the market and available to patients, while Scynexis has stopped actively promoting BREXAFEMME.

Company Financials

EPS

SCYX has released its 2025 Q3 earnings. EPS was reported at -0.17, versus the expected -0.2, beating expectations. The chart below visualizes how SCYX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

SCYX has released its 2025 Q3 earnings report, with revenue of 334.00K, reflecting a YoY change of -49.39%, and net profit of -8.59M, showing a YoY change of -205.95%. The Sankey diagram below clearly presents SCYX's revenue sources and cost distribution.